Drug Type Chemical drugs |
Synonyms |
Target |
Mechanism BET inhibitors(Bromodomain and extra terminal domain protein inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization Ohm Oncology, Inc.Startup |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Preclinical | US | 01 Jul 2019 | |
Hematologic Neoplasms | Preclinical | US | Ohm Oncology, Inc.Startup | 01 Jul 2019 |
Myelofibrosis | Preclinical | US | 01 Jul 2019 | |
Myelofibrosis | Preclinical | US | Ohm Oncology, Inc.Startup | 01 Jul 2019 |